Tonix Pharmaceuticals Announces Agreement And Initiation Of Enrollment In Phase 2 Trial With University Of Washington To Study TNX-1900 (Potentiated Intranasal Oxytocin) For Social Anxiety Disorder
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has announced an agreement and the initiation of enrollment in a Phase 2 trial with the University of Washington. The trial will study TNX-1900, a potentiated intranasal oxytocin, for the treatment of social anxiety disorder.
July 17, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals is initiating a Phase 2 trial for TNX-1900, a potential treatment for social anxiety disorder. This could potentially lead to a new revenue stream if the trial is successful.
The initiation of a Phase 2 trial is a significant step in the development of a new drug. If the trial is successful, it could lead to the drug being approved for use, which would create a new revenue stream for Tonix Pharmaceuticals. This could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100